ArticleTrials2025
Ultrashort wave therapy for chronic rhinosinusitis with nasal polyps: protocol for a randomized, double-blind, sham-controlled trial.
Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Potential effect and mechanism of ultrashort wave therapy in mice with chronic rhinosinusitis.Biomedical reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundChronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by persistent sinonasal inflammation and substantially impairs quality of life. Current treatments, including corticosteroids, surgery, and biologics, are limited by side effects and high recurrence rates. Ultrashort wave (USW) therapy, a non-invasive modality with purported anti-inflammatory effects, lacks robust evidence for its efficacy in CRSwNP.
methodsThis single-center, double-blind, sham-controlled trial will randomize 150 patients with CRSwNP to receive either active USW therapy (50 mA, 27.12 MHz) or sham treatment for 20 min daily over 2 weeks, alongside standard medical care. The sole primary outcome is the change in the 22-item Sino-Nasal Outcome Test (SNOT-22) score from baseline to the 12-month follow-up. Key secondary outcomes include the change in the Lund-Kennedy endoscopic score at the 12-month follow-up. The primary outcome will be analyzed using a linear mixed-effects model, and sensitivity analyses will be conducted to handle missing data. DISCUSSION: This trial aims to address a critical evidence gap regarding the efficacy of USW therapy for CRSwNP. If effective, USW therapy could offer a non-invasive adjunct, potentially reducing the burden of corticosteroids, surgery, and biologics while improving long-term patient outcomes. The findings will provide crucial evidence to inform clinical guidelines and direct future research.
trial registrationChinese Clinical Trial Registry (ChiCTR2400092411). Registered on November 16, 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.